Revision as of 01:53, 31 January 2019

Page editor		Section editor
	Ivy Abraham, MD University of Illinois at Chicago Chicago, IL		Neeta K. Venepalli, MD, MBA University of Illinois at Chicago Chicago, IL

0 regimens on this page 0 variants on this page

Liver cancer or hepatobiliary cancer comprises cancers that arise within the liver and its hepatocytes (hepatocellular carcinoma) and the biliary tract cancers, which include bile duct cancer/cholangiocarcinoma and gallbladder cancer.

Guidelines

ESMO

2016: Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. PubMed

NCCN

NCCN Guidelines - Hepatobiliary Cancers

Adjuvant therapy

Observation

back to top

Regimen

Study	Evidence	Comparator	Efficacy
Takada et al. 2002	Phase III (C)	5-FU & Mitomycin	Seems not superior
Neoptolemos et al. 2012 (ESPAC-3)	Phase III (C)	1. 5-FU & Leucovorin 2. Gemcitabine	Seems not superior

No adjuvant therapy.

Preceding treatment

Surgery

References

Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T, Nakayama T; Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002 Oct 15;95(8):1685-95. link to original article PubMed
ESPAC-3: Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW; European Study Group for Pancreatic Cancer. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012 Jul 11;308(2):147-56. Erratum in: JAMA. 2012 Nov 14;308(18):1861. link to original article PubMed

@@ Line 1: / Line 1: @@
-<!--'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].'''-->
-<!--Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]].-->
 {| class="wikitable" style="text-align:center; width:100%;"
+! colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c" |'''Page editor'''
 ! colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c" |'''Section editor'''
-! colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c" |'''Page editor'''
 |-
+| style="background-color:#F0F0F0; width:15%" |[[File:Ivy_Abraham.JPG|frameless|upright=0.3|center]]
+| style="width:35%" |<big>[[User:Ivyabraham|Ivy Abraham, MD]]<br>University of Illinois at Chicago<br>Chicago, IL</big>
 | style="background-color:#F0F0F0; width:15%" |[[File:nkv.jpg|frameless|upright=0.3|center]]
-| style="width:35%" |<big>[[User:Neetavenepalli|Neeta K. Venepalli, MD, MBA]]<br>Chicago, IL</big>
+| style="width:35%" |<big>[[User:Neetavenepalli|Neeta K. Venepalli, MD, MBA]]<br>University of Illinois at Chicago<br>Chicago, IL</big>
-| style="background-color:#F0F0F0; width:15%" |[[File:Ivy_Abraham.JPG|frameless|upright=0.3|center]]
-| style="width:35%" |<big>[[User:Ivyabraham|Ivy Abraham, MD]]<br>Chicago, IL</big>
 |-
 |}

Difference between revisions of "Periampullary adenocarcinoma"